Rare Disease Legislation

SB 1813 proposes reforms to the step therapy protocols used by state hospitals, potentially improving access to necessary treatments for rare disease patients. While the bill does not specifically mention rare diseases, changes in step therapy can significantly affect patient care and treatment options.

SB 1700 addresses fingerprinting requirements for qualified schools, but does not directly impact rare disease patients or their access to care. The bill's provisions are primarily administrative and do not include specific measures related to healthcare or rare diseases.

SB 1672 introduces reforms to the authorization process for antipsychotic drugs under the Arizona Health Care Cost Containment System (AHCCCS). This bill aims to streamline step therapy protocols, potentially improving access for patients requiring these medications, including those with rare conditions that may benefit from antipsychotic treatments.

HB 2583 addresses teacher qualifications and fingerprinting requirements for educational settings. While it primarily focuses on education, it may indirectly affect access to educational resources for rare disease patients.

HB 2483 establishes new accreditation requirements for behavioral health boards in Arizona. While it primarily focuses on behavioral health, the implications for step therapy processes may indirectly affect access to treatments for patients with rare diseases requiring behavioral health support.

HB 2530 introduces a waiting period and ultrasound requirement for abortion services in Arizona. While it primarily addresses reproductive health, it may indirectly affect access to care for patients with rare diseases who require comprehensive healthcare services.

HB 2760 outlines requirements for qualified schools receiving Empowerment Scholarship Accounts (ESAs), which may indirectly affect access to educational resources for rare disease patients. While the bill does not directly address healthcare provisions, it could influence the availability of specialized educational support for children with rare conditions.

S 1935 revises the referral standards for emergency care services in telemedicine and telehealth, enhancing access to care for patients, including those with rare diseases. This legislation aims to streamline the process for telehealth providers, potentially improving timely access to specialists.

S 3118 establishes a Remote Methadone Dosing Pilot Program in New Jersey, which aims to enhance access to treatment through telehealth services. While the bill primarily focuses on substance use treatment, it may indirectly benefit patients with rare diseases who require similar remote healthcare solutions.

S 1175 mandates the establishment of crisis intervention services programs for first responders in New Jersey. While it primarily focuses on mental health support for law enforcement and emergency personnel, it may indirectly benefit rare disease patients by improving overall healthcare access and response in crisis situations.

S 1113 mandates higher education institutions in New Jersey to establish mental health programs and services, which may include telehealth options. While this bill primarily focuses on mental health, it could indirectly benefit rare disease patients who may require mental health support.

S3000 codifies and extends the authorization for out-of-State health care practitioners and recent graduates to practice in New Jersey, enhancing access to care for patients, including those with rare diseases. This legislation supports telehealth services, which can be crucial for patients needing specialized care.

A3039 allows for the provision of telemedicine services using audio-only technology specifically for behavioral health care. This expansion of telehealth services may improve access for rare disease patients who require mental health support, particularly in underserved areas.

S1629 expands telehealth services by allowing healthcare professionals from outside New Jersey to provide care to patients within the state. This change could improve access to specialized care for rare disease patients who may have limited local options.

A2009 expands telehealth services by allowing out-of-state healthcare professionals to provide care to patients in New Jersey. This policy change could improve access to specialized care for rare disease patients who may not have local providers.

A3675 allows pharmacists to dispense HIV prophylaxis without an individual prescription, improving access to preventive care. Additionally, it mandates prescription benefits coverage, which may indirectly benefit patients with rare diseases requiring similar access to medications.

S2918 mandates that health plans provide coverage for prescription drugs related to serious mental illnesses without the need for prior authorization or step therapy. This change aims to improve access to necessary medications, although its direct impact on rare disease patients may be limited.

A1821 prohibits health insurance carriers from denying coverage for nonopioid prescription drugs in favor of opioids, which may improve access to alternative treatments for rare disease patients. This legislation aims to ensure that patients have access to necessary medications without being forced into opioid prescriptions.

A692 limits upfront costs for oral anticancer medications, providing financial relief for patients covered under specific health benefit plans. This legislation aims to reduce the burden of high out-of-pocket expenses for essential cancer treatments, which may include therapies for rare cancers.

S2810 establishes a Medicaid Managed Care Organization Oversight Program aimed at improving the management and delivery of Medicaid services. This program could enhance access to care for rare disease patients by ensuring better oversight of managed care organizations.

A2215 increases the resource threshold limit for specific Medicaid eligibility groups, potentially allowing more rare disease patients to qualify for Medicaid benefits. This change could enhance access to necessary healthcare services for those with limited financial resources.

A2230 proposes to increase the income threshold limit for specific Medicaid eligibility groups, potentially allowing more rare disease patients to qualify for essential healthcare services. This change could improve access to necessary treatments and support for those with limited financial resources.

A2023 mandates Medicaid fee-for-service coverage for managed long-term services and supports while beneficiaries await enrollment in managed care organizations. This provision aims to ensure continuity of care for patients, including those with rare diseases, during the transition period.

A2836 increases the resource threshold for specific Medicaid eligibility groups, potentially allowing more individuals, including those with rare diseases, to qualify for Medicaid benefits. This change could enhance access to necessary healthcare services for patients with limited financial resources.

S1582 proposes to increase the resource threshold for specific Medicaid eligibility groups, potentially allowing more individuals, including those with rare diseases, to qualify for Medicaid benefits. This change could improve access to necessary healthcare services for patients facing high medical costs.

S2800 expands Medicaid benefits to individuals who were formerly in foster care, ensuring they have access to comprehensive healthcare services. This policy change may improve access to necessary treatments for rare disease patients who fall within this demographic.

S915 establishes a pilot program in New Jersey to provide Medicaid coverage for remote maternal health services, potentially improving access for eligible beneficiaries. While the focus is on maternal health, the telehealth provisions may also benefit patients with rare diseases requiring remote consultations.

S1935 revises the referral standards for emergency care services in telemedicine and telehealth, potentially improving access to urgent care for patients, including those with rare diseases. This change may enhance the ability of rare disease patients to receive timely care remotely.

S839 revises reimbursement payments for providers utilizing telemedicine and telehealth services, which can enhance access to care for rare disease patients. Improved reimbursement rates may encourage more providers to offer telehealth services, potentially benefiting those with limited access to specialized care.

S2252 mandates the New Jersey Department of Health to enhance perinatal mental health services and requires health insurers to cover screening for perinatal mood and anxiety disorders. While this bill primarily focuses on mental health, it may indirectly benefit rare disease patients by improving overall maternal health services.

A1016 mandates automatic registration in the New Jersey Immunization Information System for individuals who consent to vaccination. This could enhance tracking of immunizations for newborns, indirectly benefiting rare disease patients by ensuring timely vaccinations.

S2987 mandates automatic registration in the New Jersey Immunization Information System for individuals who consent to it upon receiving a vaccine. This could enhance tracking of immunizations for newborns, indirectly benefiting rare disease patients by improving overall health data management.

S3020 mandates health benefits coverage for immunizations recommended by the Department of Health, which may include vaccines for certain rare diseases. This legislation aims to ensure that patients have access to necessary immunizations, potentially improving health outcomes for vulnerable populations.

S2611 establishes a program in New Jersey to incentivize the hiring and continued employment of individuals with developmental disabilities. This initiative aims to improve access to employment opportunities for individuals who may also be affected by rare diseases, enhancing their financial stability and independence.

A2251 establishes a limited medical benefit program for individuals losing NJ FamilyCare coverage, aiming to provide continuity of care for vulnerable populations. This program could help rare disease patients maintain access to necessary treatments during transitions in coverage.

A3576 codifies and extends the authorization for out-of-State health care practitioners and recent graduates to practice in New Jersey, enhancing access to care through telehealth services. This legislation may improve access for rare disease patients who require specialized care not available locally.

A3122 mandates health benefits coverage for family planning and reproductive health care services, including early infancy care, without cost sharing. This provision may improve access to essential newborn screening services, which can be crucial for early detection of rare diseases.

A2201 authorizes the use of remote patient monitoring devices and mandates insurance coverage for these devices by certain insurers. This legislation could improve access to care for rare disease patients who require ongoing monitoring, although its direct impact on specific rare conditions may vary.

S2434 prohibits the reporting of medical information for children without parental or guardian consent, which may impact newborn screening programs. This legislation aims to protect the privacy of children's health information, potentially affecting how rare diseases are identified and reported in newborns.

A861 prohibits automatic registration with the New Jersey Immunization Information System, which may impact the tracking of immunizations for newborns. While the bill does not directly address rare diseases, it could affect the monitoring of conditions identified through newborn screening.

S3109 mandates the Department of Banking and Insurance (DOBI) to monitor and report on mental health parity. While it primarily focuses on mental health, the implications for step therapy could indirectly affect access to treatments for rare disease patients requiring mental health support.